AZLI

Phase 2Completed
0 watching 0 views this week Active
51
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bronchiectasis

Conditions

Bronchiectasis

Trial Timeline

Dec 1, 2008 → Oct 1, 2009

About AZLI

AZLI is a phase 2 stage product being developed by Gilead Sciences for Bronchiectasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00805025. Target conditions include Bronchiectasis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT01404234Phase 3Completed
NCT00805025Phase 2Completed

Competing Products

20 competing products in Bronchiectasis

See all competitors
ProductCompanyStageHype Score
Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
77
AZD9668 + PlaceboAstraZenecaPhase 2
52
AZD5069 + PlaceboAstraZenecaPhase 2
52
AZD0292AstraZenecaPhase 2
52
TIP + TIP and placebo + PlaceboNovartisPhase 2
52
Ciprofloxacin DPI (BAYQ3939) + PlaceboNovartisPhase 3
77
Placebo to Ciprofloxacin DPI (BAYQ3939)NovartisPre-clinical
23
Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + PlaceboNovartisPhase 3
77
QBW251 + PlaceboNovartisPhase 2
52
Ciprofloxacin (Cipro, BAYQ3939) + PlaceboNovartisPhase 2
52
AZLI + PlaceboGilead SciencesPhase 3
76
Aztreonam lysineGilead SciencesApproved
84
AZLI + PlaceboGilead SciencesPhase 3
76
Itepekimab (SAR440340) + PlaceboSanofiPhase 2
51
CSL787 + PlaceboCSLPhase 1
32
CSL787 + PlaceboCSLPhase 2
51
HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3
74
HSK31858 + placeboHaisco Pharmaceutical GroupPhase 2
49
Group A + Group BBayerPre-clinical
20
BAY85-8501 + PlaceboBayerPhase 2
49